Pentostatin and Alemtuzumab for Allogeneic PBPCT

Medicine & Life Sciences

1. Pentostatin 100%
2. Alemtuzumab 91%
3. Homologous Transplantation 57%
4. Tissue Donors 51%
5. Cell Transplantation 47%
6. Immunosuppressive Agents 36%
7. Blood Cells 35%
8. Stem Cells 32%
9. Purine Nucleosides 32%
10. Adenosine Deaminase 27%
11. Chimerism 27%
12. Apoptosis 26%
13. Allogeneic Cells 23%
14. Nucleosides 23%
15. Graft vs Host Disease 23%
16. Bone Marrow Transplantation 22%
17. Myeloid Cells 22%
18. T-Cell Antigen Receptor 22%
19. Hematologic Neoplasms 22%
20. Mortality 22%
21. Neutropenia 21%
22. Renal Cell Carcinoma 21%
23. Progression-Free Survival 19%
24. Immunosuppression 19%
25. Transplantation 16%
26. Immunoglobulin G 16%
27. Monoclonal Antibodies 16%
28. Kinetics 15%
29. Health Care Outcome Assessment 14%
30. T-Lymphocytes 13%
31. Safety 12%
32. Antibodies 12%
33. Wounds and Injuries 10%